Invitrogen Corporation (NASDAQ:IVGN) provides products and services that
support academic and government research institutions and pharmaceutical and
biotech companies worldwide in their efforts to improve the human condition.
The company provides essential life science technologies for disease
research, drug discovery, and commercial bioproduction.
Invitrogen's own research and development efforts are focused on
breakthrough innovation in all major areas of biological discovery including
functional genomics, proteomics, stem cells, cell therapy and cell biology —
placing Invitrogen's products in nearly every major laboratory in the world.
Founded in 1987, Invitrogen is headquartered in Carlsbad, CA, and
conducts business in more than 70 countries around the world. The company
employs approximately 4,700 scientists and other professionals and had
revenues of approximately $1.3 billion in 2007.